ライフサイエンスコーパス: treatment period

1 eriod (approximately the last 8 weeks of the treatment period).

2 ulation (all patients who completed all four treatment periods).

3 ore or preserve SGC function well beyond the treatment period.

4 tive treatment or placebo (3:1) for a 12-day treatment period.

5 per day orally during a 12-week double-blind treatment period.

6 ebulizer) were each followed by a 4-week off-treatment period.

7 ntidepressant treatment with a preceding non-treatment period.

8 d, and a 3-week wash out separated each drug treatment period.

9 then remained stable throughout the complete treatment period.

10 he primary outcome was live birth during the treatment period.

11 ine, and tumor sizes were monitored over the treatment period.

12 ady increase in body weight of mice over the treatment period.

13 be taken at mealtimes twice daily during the treatment period.

14 etion and cholesterol efflux over the 14-day treatment period.

15 e resolved effect kinetics over the complete treatment period.

16 ium spp. populations was observed during the treatment period.

17 this trend was sustained throughout the 28-d treatment period.

18 group and the placebo group over the 6-month treatment period.

19 ng beta-agonists were not allowed during the treatment period.

20 ulin sensitivity before and after the 6-week treatment period.

21 o received methotrexate for the full 52 week treatment period.

22 experienced by adolescents during the cancer treatment period.

23 by week 2 and were sustained throughout the treatment period.

24 0 mg BID or prasugrel 10 mg OD with a 15-day treatment period.

25 S:Inv) Total score at the end of each 4-week treatment period.

26 was given for the first 4 to 6 weeks of each treatment period.

27 sities did not change significantly over the treatment period.

28 to symptoms in adolescents during the cancer treatment period.

29 le (FAS) before, during, and after a 3-month treatment period.

30 sease Activity Index <150) at the end of the treatment period.

31 roughout a 10 min pre-treatment and a 10 min treatment period.

32 r, or retinal detachment during the 12-month treatment period.

33 mmediately, 3 months, and 6 months after the treatment period.

34 hree dose levels with placebo over a 52-week treatment period.

35 e performed at the beginning and end of each treatment period.

36 nd thrombocytopenia in the early part of the treatment period.

37 ar, or retinal detachment during the 24-week treatment period.

38 porarily suppressed viral replication during treatment period.

39 logic response 12 weeks after the end of the treatment period.

40 re collected at baseline and after an 8-week treatment period.

41 ined essentially undetectable for the entire treatment period.

42 21.5 and at postnatal day 8, irrespective of treatment period.

43 end of treatment but had a relapse after the treatment period.

44 ts of forced vital capacity during a 60-week treatment period.

45 use of basic medication during the 18-month treatment period.

46 l nasal symptom score (range, 0-24) over the treatment period.

47 SEI which did not fully disappear during the treatment period.

48 2 sham dogs died suddenly during the 3-month treatment period.

49 editary angio-oedema observed in each 4 week treatment period.

50 ith treatment onset and completed within the treatment period.

51 ber of bleeding episodes during each 6-month treatment period.

52 was completed or nearly completed within the treatment period.

53 in glargine U100 were also seen for the full treatment period.

54 bleeding during and up to 48 hours after the treatment period.

55 rterial spin labeling MRI at the end of each treatment period.

56 ade 2 skin toxicities during the 6-week skin treatment period.

57 t transfusion at any time during the 4-cycle treatment period.

58 as examined histologically at the end of the treatment period.

59 performed at baseline and at the end of each treatment period.

60 ent remained constant throughout the 6-month treatment period.

61 with ISS when re-assessed 4 years after the treatment period.

62 % MQX-503 gel or matching placebo during the treatment period.

63 nalyses of first events during the scheduled treatment period.

64 ased NR1 mRNA expression after a 12 and 48 h treatment period.

65 n hippocampal cultures but only after a 48 h treatment period.

66 ormed in a subset of birds at the end of the treatment period.

67 matism decreased in magnitude over the 7-day treatment period.

68 ficant amounts of astigmatism throughout the treatment period.

69 fects were seen at 7 d and lasted beyond the treatment period.

70 s and more deaths during the initial 16-week treatment period.

71 d with accelerated bone loss over the 5-year treatment period.

72 weeks for a total of 20 doses over an 8-week treatment period.

73 evaluated at baseline and at the end of the treatment period.

74 372) for the remainder of a 5-year endocrine treatment period.

75 e of antidrug antibodies detected during the treatment period.

76 ortin-positive neuroblasts at the end of the treatment period.

77 articipants, of whom 96 completed the 6-week treatment period.

78 in estimated GFR (eGFR) trajectory over the treatment period.

79 e to a significant degree over the rituximab treatment period.

80 ts who reported a fracture event in the post-treatment period.

81 = 35; placebo, n = 33) completed the 28-week treatment period.

82 entage of patients who completed the 24-week treatment period.

83 ed disability progression in the prebaseline treatment period.

84 aseline and 15.8 (5.6-57.6) over the 12 week treatment period.

85 in part B, 33 of whom completed the 24 week treatment period.

86 nstant was 0.033+/-0.009mm(3)/day during the treatment period.

87 cortisone in vasovagal syncope over a 1-year treatment period.

88 ne, for 2 or more weeks during a 4-week post-treatment period.

89 r both in combination, for the core 12-month treatment period.

90 95% CI, -4.6 to -0.2) 7 to 14 days after the treatment period.

91 e response sustained response throughout the treatment period.

92 ct of caplacizumab was maintained during the treatment period.

93 nd similar between treatments over the whole treatment period.

94 , assessed 7 to 14 days after the end of the treatment period.

95 ared with enalapril, over a relatively short treatment period.

96 kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods.

97 ht-fasted subjects before and after the 6-mo treatment periods.

98 essed by questionnaire at the end of the two treatment periods.

99 ged 3-219 months) were much the same between treatment periods.

100 eriod, with a 28-day washout between the two treatment periods.

101 All patients completed both treatment periods.

102 FVC, 70.4% predicted), and 20 completed both treatment periods.

103 of apnoeas were similar between control and treatment periods.

104 ay) was given to all participants during the treatment periods.

105 ncreased in magnitude at the end of the 28-d treatment periods.

106 e self-administered subcutaneously in 28-day treatment periods.

107 a randomized crossover design with two 8-wk treatment periods.

108 142 participants had follow-up data in both treatment periods.

109 of hot flushes during the final week of both treatment periods.

110 At the end of the treatment period (12 months), the cardiac phenotype was

111 Risk differences during the randomized treatment period (12 to 30 months) for ischemic (MI and/

112 Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months

113 For the latter post-treatment period (180 min peak) the stronger relationshi

114 During the 24-week treatment period, 2 (2.9%), 3 (3.4%), 0, and 4 (5.0%) pa

115 In the first treatment period, 31 patients were allocated to allopuri

116 ients who completed the 52-week double-blind treatment period, 345 entered the 24-week extension, and

117 d with lower rates of anemia over the entire treatment period (48 weeks), as well as a lower rate of

118 temperature effects during the initial post-treatment period (60 min peak); possible effects from mo

119 At the end of the 12-week treatment period, 62% of patients who received the 800-m

120 During the 24-week open-label treatment period, 70 [80%] of 87 patients achieved plate

121 During the treatment period, all the patients tested negative for T

122 he placebo group; at 42 to 56 days after the treatment period, an invasive infection had developed in

123 e-chain-reaction (rt-PCR) assays, during the treatment period and 10 months after the end of treatmen

124 multinational clinical trial with a 24-week treatment period and 28-week follow-up conducted between

125 ebo-controlled clinical trial with a 12-week treatment period and a further 12-week follow-up conduct

126 h a reduction in relapse rates during the re-treatment period and a more prolonged period of remissio

127 ovement in quality of life at the end of the treatment period and a reduction in the number of severe

128 and the ASRS, before and during the 3-month treatment period and after a 1-month washout period.

129 were monitored for adverse events during the treatment period and assessed for combined rhinoconjunct

130 ed multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted

131 ntly observed clonal shifts during the early treatment period and its potential association with adve

132 take; however, the effect decreased over the treatment period and rapidly disappeared when drug treat

133 on outcomes were assessed during the 3-month treatment period and the 3-month follow-up period.

134 ssessed over 24 weeks, including the 12-week treatment period and the subsequent 12 weeks after study

135 A longer treatment period and/or a higher dose may improve the cl

136 nt randomization; 26 patients completed both treatment periods and could be evaluated per protocol fo

137 tilised lasting 42 weeks, with three 10-week treatment periods and two 6-week washout periods.

138 33 patients completed all four treatment periods and were included in the primary outco

139 ic causes during or within 14 days after the treatment period, and during the follow-up period, one p

140 f the study, all of whom completed the 4 day treatment period, and eight of whom took part in part B.

141 n-in period, concurrent treatment during the treatment period, and instrument version significantly i

142 ery 3 weeks for up to 24 weeks in an initial treatment period, and patients who did not show an impro

143 es rainfall and temperature covariates, drug treatment periods, and population variability is capable

144 At the end of the treatment period, animals were tested for locomotor acti

145 maximum preinjection IOP during the 24-month treatment period; any occurrence of absolute preinjectio

146 e properly managed particularly if prolonged treatment periods are required.

147 microarray hybridizations at the end of the treatment period as well as immediately and 30 minutes a

148 convulsive-seizure frequency over a 14-week treatment period, as compared with a 4-week baseline per

149 In the 4-week post-treatment period, ascending dose cohorts underwent a fur

150 IOP was measured at the end of each treatment period at 4, 6, and 8 pm.

151 g better quality of life), at the end of the treatment period at week 14, after the 2-week course of

152 ears; 57 women [63%]), 56 had completed both treatment periods at the time of the study's termination

153 After the 4-week treatment period, both groups were brought back to under

154 efits for organ protection during the 2-year treatment period, but significant benefits for pain, acu

155 ined SSA disability benefits over the 2-year treatment period, but there were also some unintended ad

156 The microbiota was then subjected to a 4-wk treatment period by adding 5 mL of sterile peptone water

157 placebo run-in period with values in the ICS treatment period by using paired t tests.

158 At the end of each treatment period, CBFV by transthoracic Doppler echocard

159 ilar across groups (neoadjuvant and adjuvant treatment periods combined).

160 al was 90.9% (83.5%-99%) over the biological treatment period compared with 58.7% (43.3%-79.7%; P=0.0

161 icantly less functional impairment after the treatment period compared with patients with normal base

162 of platelet reactivity throughout the entire treatment period compared with placebo (primary end poin

163 re significantly reduced during the anakinra treatment period compared with those seen after placebo.

164 es were lower during the combined idelalisib treatment periods compared with placebo (treatment diffe

165 A 10-week, two-treatment period, crossover design was used.

166 ffects of OC000459 persisted into the second treatment period despite a 3-week washout phase.

167 oncentration increased (p < 0.01) during the treatment period, due mainly to significant increased le

168 At the end of the treatment period, each animal was sedated with propofol

169 Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, b

170 nuary 2014-January 12, 2016) for two 32-week treatment periods, each with a 16-week titration and a 1

171 target crossover trial including two 32-week treatment periods, each with a 16-week titration period

172 At the end of a 10-week treatment period, echocardiography revealed reduced card

173 crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per k

174 6 common symptoms in adolescents during the treatment period: fatigue, sleep-wake disturbances, naus

175 ed From AMD Parents [LIMPIA]) with a 6-month treatment period, followed by a 6-month follow-up period

176 reached maximal levels on day 2 of the post-treatment period for both doses (mug kg(-)(1)): 5920 and

177 y monitoring during the 5-year pharmacologic treatment period for osteoporosis in women.

178 Patients were seen weekly during a 4-week treatment period for safety assessments, best-corrected

179 d of open-label inhaled fluticasone, and the treatment periods for subjects randomized to (1) continu

180 ferences were also observed for the combined treatment periods for total symptom scores, nasal airflo

181 13 in the chemotherapy group died during the treatment period (from the day of the first dose of stud

182 By the end of the treatment period, hot flash scores (frequency x average

183 lf-administration at the beginning of a 14 d treatment period; however, the number of nicotine infusi

184 mber and percentage of adverse events in the treatment period in an intention-to-treat analysis.

185 n was 98%, and 86% of subjects completed the treatment period in both groups.

186 9.1 mmol/L (p<0.001) during the combination treatment period in cohort 1.

187 energy x-ray absorptiometry over the 12 week treatment period in eligible patients who had at least o

188 was generally well-tolerated over the 4-year treatment period in patients with SLE, which suggests th

189 hloride concentration during the combination treatment period in the intention-to-treat population an

190 toring was done on day -1 and day 10 of each treatment period in this study.

191 among placebo patients during the prednisone treatment period in VISUAL-1 was statistically higher th

192 le-blind period entered a 24 week open-label treatment period in which all patients received eltrombo

193 n-in period, subjects were randomized into 3 treatment periods in a crossover clinical trial, with a

194 bo twice daily during two consecutive 14-day treatment periods in a crossover sequence.

195 per week for at least 9 weeks of the 12-week treatment period including at least three of the last 4

196 At 7 to 14 days after the treatment period, invasive infections had developed in 2

197 The post-treatment period is characterized by gradual recovery fr

198 The treatment period lasted 24 months from randomisation.

199 on state significantly altered by ABA over a treatment period lasting 5-30 min.

200 Although the 8-week treatment period limits interpretation to acute treatmen

201 Over the treatment periods, mean+/-SD LDL cholesterol reductions

202 During the first off-treatment period (median, 37.4 weeks; range, 13.4 weeks

203 n approximately </=10 g/dL) during the study treatment period (n = 500) were assigned to groups that

204 Serious bleeding during the treatment period occurred in 10 patients in the DrotAA g

205 iac end point increases during the scheduled treatment period of 1 year, but it remains relatively co

206 (Q4W), alternating with placebo for a total treatment period of 12 weeks.

207 s were significantly regulated by ABA over a treatment period of 20-24 h.

208 During a median treatment period of 23.9 months, 23 patients taking aspi

209 After the treatment period of 28 days, each group was further subd

210 nuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recomm

211 acizumab 1 to 15 times, resulting in a total treatment period of 42 to 1182 days.

212 o warfarin or matching placebo for a planned treatment period of 48 weeks.

213 ed by 900 mg every 14 +/- 2 days for a total treatment period of 52 weeks.

214 After a treatment period of 5days, IN applied FTA loaded HNPs ac

215 ted ipilimumab (182 [39%] during the initial treatment period of four doses).

216 IN OUTCOME MEASURES: Rate during the 48-week treatment period of protocol-defined pulmonary exacerbat

217 ant study drug dose, followed by an adjuvant treatment period of up to 1 year.

218 e found to be slightly less effective during treatment periods of 1 to 2 years, but they were associa

219 bjects (n=29) participated in two randomized treatment periods of daily placebo or PF-04958242 for 5

220 greatest average change in BMD during early treatment periods of IAD with a smaller average change t

221 was 3070 before and 4651 after the low-salt treatment period, on average.

222 P = .033), and 9.3 months in the 1-year post-treatment period (P = .054).

223 t changes in total anaerobic counts over the treatment period (P = 0.96) differed between treatment g

224 ignificantly from baseline to the end of the treatment period (P<0.001).

225 arthroses in a single joint during a 6-month treatment period) (P<0.001).

226 After 6 monthly injections (treatment period), patients meeting prespecified criteri

227 During each 14-day treatment period, patients received balanced doses of an

228 Over the treatment period, patients receiving placebo or bosutini

229 After each treatment period, patients underwent CCA ultrasonography

230 During the treatment period, patients, investigators, their site pe

231 ry outcomes were the composite at 42 months (treatment period plus 24-month follow-up), as well as ea

232 During the entire treatment period, pooled exposure-adjusted incidence rat

233 ined asthma exacerbations during the 48-week treatment period (primary endpoint).

234 Outside of these treatment periods rats were fed a standard diet (1.1 mg/

235 gen level remained reduced during the entire treatment period, reaching a maximal reduction of 76% af

236 During the 4-week treatment period, recovery was significantly faster in t

237 shorter (6-9-month) or longer (24-30-month) treatment periods relative to subjects' best predose wal

238 products at port facilities due to the short treatment period required, but it is vented from fumigat

239 h between doses and contributing to the long treatment periods required for TB.

240 rved between randomized groups after 12-week treatment-period (SCORAD-score pre-/post-intervention: B

241 d serum creatinine levels during the 48-week treatment period; six patients had alanine aminotransfer

242 On day 5 of each treatment period, subjects underwent a ketamine infusion

243 During the treatment periods, subjects consumed all of the calories

244 support was significantly higher during the treatment period than at baseline and end of therapy, Z

245 ptom experience deteriorated more during the treatment period than at the baseline, Z >/= -1.97, p </

246 stress were significantly higher during the treatment period than at the end of treatment.

247 re significantly less likely to complete the treatment period than those assigned to the control cond

248 nt with endarterectomy after the 30-day post-treatment period, the 8-year incidence and hazard ratio

249 During the treatment period, the FEV(1) slope was -12+/-2 ml per mo

250 erms of absolute risk averaged over a 1-year treatment period, the increase in risk attributable to I

251 During the 46-week treatment period, the mean number of days with asthma sy

252 During the 18-month treatment period, the primary outcome occurred in 6 of 1

253 After the treatment period, the tumors in all groups grew at simil

254 nt and placebo groups during the combination treatment period; the most commonly reported events were

255 Four deaths occurred during the 12-week treatment period, three in NightLyte (upper gastrointest

256 During the 30-week continuation treatment period, time to remission did not differ signi

257 omparing the HAE attack incidence during the treatment period to the historical attacks over the prev

258 During the first treatment period, treatment with OC000459 significantly

259 ry rates of children at the end of the 16-wk treatment period trended higher in the RUSF group (73%)

260 eks (n=151), of whom 383 (85%) completed the treatment period up to week 52.

261 addition provides lasting benefit beyond the treatment period via enhanced U(VI) adsorption to sedime

262 During the final 9 d of the treatment period, volunteers collected all urine and fec

263 percentage change in BMD during the first on-treatment period was -3.4% (P < .001) for the spine and

264 The mean breakthrough attack rate during the treatment period was 0.4 attacks/week (95% CI 0.28-0.56)

265 Treatment period was 1 year with a 1-year follow-up.

266 ence in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the

267 The maximum treatment period was 2 y or until occurrence of a CRBSI

268 ade 2 skin toxicities during the 6-week skin treatment period was 29% and 62% for the pre-emptive and

269 e median oxygen saturation at the end of the treatment period was 99% among patients assigned to oxyg

270 reatment on alternate days during a five-day treatment period was able to restore a healthy ocular su

271 A 24-week treatment period was followed by 12 weeks of core follow

272 The 12-week treatment period was followed by a 6-week single-blind p

273 Each buspirone treatment period was followed by saline control treatmen

274 he BCVA gain achieved in the initial 6-month treatment period was maintained with an additional 12 mo

275 ade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre

276 Each 4-wk treatment period was separated by 4-wk washout intervals

277 Each treatment period was separated by a 3-4 week washout per

278 4) cardiac allograft survival after a 10-day treatment period was studied for various regimens of R34

279 t of platelet reactivity at the end of the 2 treatment periods was lower for ticagrelor (32.9 PRU, 95

280 The order of the 2-week treatment periods was randomized, and a 3-week wash out

281 ponders, which was maintained throughout the treatment period, was 25.2% (95% CI 21.5% to 28.8%) and

282 At baseline and after each treatment period, we assessed insulin sensitivity (hyper

283 oup, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related.

284 oncentrations between yolk and white in post treatment period were found.

285 The mean scores at the end of the 6-week treatment period were lower for the ECT group than for t

286 lth-related quality of life over the 48-week treatment period were observed.

287 on treatment at the end of the double-blind treatment period were offered open-label enzalutamide at

288 d completed the initial 52-week double-blind treatment period were then allowed to enter a 24-week op

289 The treatment periods were followed by a 14-day single-blind

290 The two treatment periods were separated by a 3-month washout pe

291 rom baseline for >/= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of

292 At the end of the 7-day treatment period, whereas only 8.6% of the control chick

293 e were measured on days 1 and 7 of each 1-wk treatment period with a 1-wk washout between testings.

294 both to identify significant change over the treatment period with a given regimen and to compare cha

295 ses, complete resolution occurred within the treatment period with no recurrence for at least 3 month

296 These findings indicate that a prolonged treatment period with raloxifene might be required to pr

297 ion, FR 10 schedule) during continuous 7-day treatment periods with saline or the agonist medication

298 xib group during or within 14 days after the treatment period, with an estimated relative risk of 2.6

299 ong the three study groups at the end of the treatment period, with mean scores of 35.0 (95% confiden

300 rs have proven to be well tolerated for long treatment periods, with minimal adverse events, in the o